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S U M M A R Y
Background: In 1997 the US Centers for Disease Control and Prevention (CDC) and the World Health
Organization (WHO) reported high proportions of drug-resistant Mycobacterium tuberculosis in three
Mexican states: Sinaloa, Baja California, and Oaxaca. In 2006, we showed that resistance to anti-
tuberculosis drugs remained frequent in Sinaloa.
Objectives: The objectives of this study were to describe drug-resistant tuberculosis (TB) trends and to
investigate the probability that patients acquire resistance to ﬁrst-line anti-TB drugs on recurrence after
treatment in Sinaloa.
Methods: Sputum specimens were collected from patients diagnosed with TB at all the health care
institutions of Sinaloa during 1997–2005. Isolates were tested for susceptibility to ﬁrst-line drugs.
Results: Among 671 isolates tested from 1997 to 2002, the overall resistance rate was 34.9% (95%
conﬁdence interval (CI) 31.2–38.4) with a 1.2% increase per year (Chi-square = 4.258, p = 0.03906). The
prevalence of multi-drug resistance (MDR) was 17.9% (95% CI 14.9–20.7) with a 1.2% increase per year
(Chi-square = 8.352, p = 0.00385). Of 50 patients registered twice between 1997 and 2005, 15 were fully
susceptible at ﬁrst registration, of whom six (40%) acquired drug resistance. Of 35 cases with any drug
resistance at ﬁrst registration, 21 (60%) came to acquire resistance to at least one other drug.
Conclusions: The proportion of drug-resistant TB increased during 1997–2005 in Sinaloa. Major efforts
are needed to prevent the further rise and spread of drug-resistant and MDR TB.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Despite efforts to control tuberculosis (TB), this disease
continues to be one of the main public health problems in the
world,1,2 particularly in developing countries.3,4 TB caused by
Mycobacterium tuberculosis (M. tuberculosis) is one of the most
important reemerging infectious diseases. Currently a third of the
world’s population is infected with M. tuberculosis,5 and nearly 9
million new cases appear and 2 million deaths occur each year.6
Furthermore, the emergence and spread of drug-resistant strains
of M. tuberculosis reduce anti-TB treatment options and make the
control of these infections difﬁcult.7–12 In 2006, extensively drug-
resistant strains (XDR) were reported from several regions of the
world; these present resistance even to second-line anti-TB* Corresponding author. Tel.: +52 667 7538802; fax: +52 667 7538801.
E-mail address: adriancanizalez@gmail.com (A. Canizalez-Roman).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.01.001treatment and represent a serious worsening of the epidemiologi-
cal magnitude of TB worldwide.13
The World Health Organization (WHO) and the International
Union Against Tuberculosis and Lung Diseases (IUATLD) have
estimated that 50 million people worldwide are infected with
drug-resistant (DR) M. tuberculosis strains, which present resis-
tance to at least one of the ﬁrst-line anti-TB drugs.5,14 These
organizations launched the Global Project on Anti-Tuberculosis
Drug Resistance Surveillance, which uses standardized methods to
measure the prevalence of drug resistance and assess its
correlation with indicators of TB control.3,14–16 Though the Global
Project (WHO/IUATLD) has been operating since 1994, few
countries and regions have reported data, and in some cases there
have been discrepancies between the information reported by one
organization and another.17 Data from repeated surveys employ-
ing comparable methodologies over several years are essential to
determine with any certainty in which direction the prevalence of
drug resistance is moving.16ses. Published by Elsevier Ltd. All rights reserved.
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drugs have shown thatDR is presentworldwide and thatmultidrug-
resistant TB (MDR-TB; resistant at least to isoniazid and rifampin) is
present inmost of theworld.3 DR- andMDR-TBhave been identiﬁed
in Mexico,4 despite the efforts of a National Tuberculosis Program
based on the directly observed treatment strategy (DOTS). The US
Centers for Disease Control and Prevention (CDC) andWHO/IUATLD
(Global Project) reported high DR proportions in a unique national
survey undertaken in 1997, covering three states in Mexico: Baja
California, Oaxaca, and Sinaloa.18
In particular, moderate to high TB rates19 have been found in
Sinaloa, a state with approximately 2 534 000 inhabitants in the
northwest of Mexico. Recently we reported that DR- and MDR-TB
are still frequently found in this state and are associated with anti-
TB treatment history.20 Additional information is sorely needed in
order to assist in the control of TB, the identiﬁcation of future
trends in DR and MDR, and the design of guidelines for the
appropriate treatment of DR cases. Accordingly, the aim of this
work was to analyze the behavior ofM. tuberculosis (DR and MDR)
in Sinaloa over time.
2. Materials and methods
The present study was based on an analysis of the results of
susceptibility testing of M. tuberculosis strains isolated from
patients with clinical symptoms or a diagnosis of pulmonary TB,
whose cases were attended to at the Public Health Laboratory in
Sinaloa, Mexico, from January 1997 through December 2005.
2.1. Data management and analysis
Patients were included from all the health care institutions of
Sinaloa,with themajority coming fromthe SSA (Mexican Secretariat
of Health) and IMSS (Mexican Institute of Health Care). We
conducted three different stages of drug resistance analysis
considering new cases, previously treated cases, and all TB cases.
In the ﬁrst stage, which focused on the period 1997–2002, we
calculated the proportions of DR and MDR and analyzed trends in
these over time. We did a follow-up in the second stage of the
analysis for 2003–2004, calculating DR and MDR proportions and
comparing these data with those of the period 1997–2002 (ﬁrst
stage). Finally, in a third stage of the analysis, we analyzed drug
resistancedata (DRandMDR)of re-registeredTBpatients from1997
to 2005 (recurrent or chronic), selecting those patients with two
isolates ofM. tuberculosis in order to compare DR andMDR between
the ﬁrst and the second strains. Demographic data and treatment
history were collected by the physician through patient interview.
2.2. Drug resistance deﬁnitions
Weclassiﬁed resistance to anti-TB drugs according to treatment
history. The term ‘new case’ (resistance among new cases; primaryTable 1
Patient distribution by age, sex, and treatment history, according to study stage
Stage Study/analysis Patients
New Pre
tre
1; 1997–2002 Analysis of drug-resistant TB trends 425a 159
2; 2003–2004 Comparison of drug-resistant TB;
stages 1 and 2
40 26
3; 1997–2005 Analysis of drug-resistant TB in
patients with recurrent disease
who had two isolates of
M. tuberculosis
15 (30 strains) 35
a Patients provided data on TB treatment history (87.0%; 584/671).resistance) refers to patients with pulmonary TB who had either
never been treated with ﬁrst-line anti-TB drugs or had received
them for less than 1 month. A ‘previously treated case’ (resistance
among previously treated cases; secondary or acquired resistance)
refers to patients who had been treated for 1 month or more. ‘All
cases’ (resistance among all cases; combined resistance) refers to
all patients without considering their history of anti-TB treatment.
We deﬁned drug resistance (DR) as resistance to at least one of the
ﬁrst-line anti-TB drugs, and multi-drug resistance (MDR) as
resistance to at least isoniazid (INH) and rifampin (RIF).
2.3. Laboratory methods
M. tuberculosis was isolated from sputa in Lowenstein–Jensen
medium. Tests for drug susceptibility to INH, RIF, streptomycin
(SM), ethambutol (EMB), and pyrazinamide (PZA) were carried out
at the National Diagnostic and Epidemiologic Reference Institute
(Mexico City) by use of the radiometric BACTEC 460 TB system
(Becton Dickinson, Towson, MD, USA).
2.4. Statistical analysis
Statistical analysis was done with Epi-Info (version 6.04; CDC,
Atlanta, GA, USA and WHO, Geneva, Switzerland). We carried out
linear regression to evaluate DR and MDR trends, Chi-square to
evaluate signiﬁcance, and R2 to indicate the proportion of variation.
We also used odds ratios (OR) as a measure of association, and
calculated conﬁdence intervals to 95% (95% CI). We considered a p-
value of <0.05 to be statistically signiﬁcant.
3. Results
Drug resistance data for the period 1997–2005 were classiﬁed
and analyzed as shown in Table 1. There were no important
variations in age or sex of the patients across the stages studied.
3.1. Stage 1: DR and MDR magnitudes and their trends from 1997 to
2002
3.1.1. DR and MDR magnitudes from 1997 to 2002
The proportion of anti-TB drug resistance in all cases was
calculated from 671M. tuberculosis isolates; 234 (34.9%, 95% CI
31.2–38.4) showed resistance to at least one anti-TB drug (DR) and
120 (17.9%, 95% CI 14.9–20.7) showed resistance to at least INH
and RIF (MDR) (Table 2). The frequency of anti-TB drug resistance
was highest to INH and RIF, at 29.8% and 19.2%, respectively. Of all
patients tested, 87.0% (584/671) informed the attending physician
of their anti-TB treatment history.
Among the new cases (72.8%, 425/584), 90 (21.2%, 95% CI 17.3–
25.0) showed DR and 21 (4.9%, 95% CI 2.8–7.0) showed MDR. The
frequency of anti-TB drug resistance was highest to INH, SM, and
RIF, at 17.2%, 11.3%, and 6.1%, respectively.Sex (%) Age (years)
viously
ated
All Male Female Mean Range
a 671 66.8 33.2 40.9 10–91
66 63.6 36.4 41.2 13–76
(70 strains) 50 (100 strains) 68 32 39.7 19–78
Table 2
Proportions of drug-resistant Mycobacterium tuberculosis for the periods 1997–2002 and 2003–2004; Sinaloa, Mexico
Tested M. tuberculosis strains New cases (%) Previously treated cases (%) All cases (%)
1997–2002 2003–2004 1997–2002 2003–2004 1997–2002 2003–2004
Total tested 425 40 159 26 671 66
Fully sensitive 335 (78.8) 33 (82.5) 56 (35.2) 8 (30.8) 437 (65.1) 41 (62.1)
Any resistance (DR) 90 (21.2) 7 (17.5) 103 (64.8) 18 (69.2) 234 (34.9) 25 (37.9)
Isoniazid 73 (17.2) 0 94 (59.1) 18 (69.2) 200 (29.8) 18 (27.3)
Rifampin 26 (6.1) 0 80 (50.3) 12 (46.2) 129 (19.2) 12 (18.2)
Ethambutol 20 (40.7) 0 48 (30.2) 12 (46.2) 83 (12.4) 12 (18.2)
Streptomycin 48 (11.3) 7 (17.5) 52 (32.7) 7 (26.9) 122 (18.2) 14 (21.2)
Pyrazinamide 14 (3.3) 0 52 (32.7) 10 (38.5) 85 (12.7) 10 (15.2)
Multi-drug resistance (MDR)a 21 (4.9) 0 76 (47.8) 12 (46.2) 120 (17.9) 12 (18.2)
Number of drugs resistant to:
1 41 (9.6) 7 (17.5) 13 (8.2) 3 (11.5) 68 (10.1) 10 (15.2)
2 24 (5.6) 0 22 (13.8) 1 (3.8) 52 (7.7) 1 (1.5)
3 13 (3.1) 0 25 (15.7) 4 (15.4) 44 (6.6) 4 (6.1)
4 7 (1.6) 0 21 (13.2) 8 (30.8) 35 (5.2) 8 (12.1)
5 5 (1.2) 0 22 (13.8) 2 (7.7) 35 (5.2) 2 (3.0)
a Resistance to at least isoniazid and rifampin.
Figure 1. Trends in multi-drug resistance (MDR) and overall resistance (DR) in
Mycobacterium tuberculosis; Sinaloa, Mexico, 1997–2002. (A) Trend in overall
resistance (%) among all tuberculosis cases (DR). Chi-square for linear trend = 4.258,
p = 0.03906. Linear regression formula: R2 = 0.0593, X-coefﬁcient, 1.2017. (B) Trend
in MDR (%) among all tuberculosis cases. Chi-square for linear trend = 8.352,
p = 0.00385. Linear regression formula: R2 = 0.0616, X-coefﬁcient, 1.2263.
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95% CI 57.3–72.1) showed DR and 76 (47.8%, 95% CI 40.0–55.5)
showed MDR. INH and RIF were the drugs to which the highest
resistance was found, at 59.1% and 50.3%, respectively (Table 2).
Notably, more than half of the patients with DR M. tuberculosis
isolates showed MDR (51.3%; 120/234). Previously untreated
patients showed M. tuberculosis isolates with a lower mean
resistance (90/425; 21.2%) than the group of patientswith a history
of previous anti-TB treatment (103/159; 64.8%; Chi-
square = 99.43, p = 0.0000001). Previous anti-TB treatment was
associated with drug resistance (OR = 6.85).
3.1.2. DR and MDR trends from 1997 to 2002
DR and MDR in the ‘all cases’ patient group showed an
increasing trend over time that turned out to be statistically
signiﬁcant (DR: 1.20% per year, Chi-square = 4.258, p
trend = 0.03906; MDR: 1.22% per year, Chi-square = 8.352, p
trend = 0.00385) (Figure 1). The differences in trends for the
new cases and previously treated cases groups did not reach
statistical signiﬁcance.
3.2. Stage 2: Dynamics of drug resistance over time (2003–2004)
The proportions of DR and MDR in this period were both very
similar to those found in the previous phase (1997–2002),
although with some variations. For all cases in the period 2003–
2004 there was 37.9% (25/66) DR and 18.2% (12/66) MDR,
compared to 34.9% (234/671) DR and 17.9% (120/671) MDR
during the period 1997–2002 (Table 2). Resistance to INH and RIF
for 2003–2004 was 27.3% (18/66) and 18.2% (12/66), respectively,
compared to 29.8% (200/671) and 19.2% (129/671), respectively,
reported in the previous period.
Among previously treated cases during 2003–2004, DR and
MDR were 69.2% (18/26) and 46.2% (12/26), respectively, while in
the previous stage they were 64.8% (103/159) and 47.8% (76/159),
respectively. Resistance to INH increased from 59.1% (94/159) to
69.2% (18/26), while that to RIF decreased from 50.3% (80/159) to
46.2% (12/26). Among new cases, DR decreased from 21.2% (90/
425) to 17.5% (7/40), whileMDR and anti-TB drug resistance to INH
and RIF decreased to 0% (Table 2).
3.3. Stage 3: Evaluation of DR and MDR among re-registered TB
patients from 1997 to 2005
For the period 1997–2005 we found 50 TB patients with two
isolates of M. tuberculosis (100 isolates total), of whom 70% (35/50) had received treatment for TB and 30% (15/50) had not
(Table 3).
Amongnewcases (15patients, 30 isolates), therewere important
increases in DR (26.7%) and MDR (40%). The highest increases were
to INH (40%) and RIF (33.3%). Drug resistance to only one drug
declined 20%, but resistance to two drugs increased 6.7%, to three
drugs increased 33.3%, and to four drugs increased 6.7%. Resistance
to ﬁve drugs remained constant (0% change) at 6.7%.
Among previously treated cases (35 patients, 70 isolates), there
were moderate increases in DR (2.9%) andMDR (8.6%). The highest
increases in resistance were to EMB (40%) and PZA (37.1%). There
was a decrease in resistance to one drug of 11.4%, to two drugs of
5.7%, and to three drugs of 11.4%. Resistance to four drugs
Table 3
Drug resistance in the ﬁrst and second Mycobacterium tuberculosis isolates; Sinaloa, Mexico, 1997–2005
Anti-TB drugs M. tuberculosis (%)
First isolate Second isolate Difference
New cases
(n=15)
Previously
treated cases
(n=35)
All cases
(n=50)
New cases
(n=15)
Previously
treated cases
(n=35)
All cases
(n=50)
New cases
(n=15)
Previously
treated cases
(n=35)
All cases
(n=50)
Isoniazid 2 (13.3) 28 (80) 30 (60) 8 (53.3) 31 (88.6) 39 (78) 6 (40) 3 (8.6) 9 (18)
Rifampin 2 (13.3) 24 (68.6) 26 (52) 7 (46.7) 26 (74.3) 33 (66) 5 (33.3) 2 (5.7) 7 (14)
Pyrazinamide 1 (6.7) 12 (34.3) 13 (26) 4 (26.7) 25 (71.4) 29 (58) 3 (20) 13 (37.1) 16 (32)
Ethambutol 1 (6.7) 11 (31.4) 12 (24) 3 (20) 25 (71.4) 28 (56) 2 (13.3) 14 (40) 16 (32)
Streptomycin 2 (13.3) 16 (45.7) 18 (36) 4 (26.7) 20 (57.1) 24 (48) 2 (13.3) 4 (11.4) 6 (12)
Any resistance
(DR)
4 (26.7) 31 (88.6) 35 (70) 8 (53.3) 32 (91.4) 40 (80) 4 (26.7) 1 (2.9) 5 (10)
Multi-drug resistance
(MDR)a
1 (6.7) 22 (62.9) 23 (46) 7 (46.7) 25 (71.4) 32 (64) 6 (40) 3 (8.6) 9 (18)
Number of drugs
resistant to:
1 drug 3 (20) 4 (11.4) 7 (14) 0 0 0 3 (20) 4 (11.4) 7 (14)
2 drugs 0 7 (20) 7 (14) 1 (6.7) 5 (14.3) 6 (12) 1 (6.7) 2 (5.7) 1 (2)
3 drugs 0 10 (28.6) 10 (20) 5 (33.3) 6 (17.1) 11 (22) 5 (33.3) 4 (11.4) 1 (2)
4 drugs 0 6 (17.1) 6 (12) 1 (6.7) 6 (17.1) 7 (14) 1 (6.7) 0 1 (2)
5 drugs 1 (6.7) 4 (11.4) 5 (10) 1 (6.7) 15 (42.9) 16 (32) 0 11 (31.4) 11 (22)
a Resistance to at least isoniazid and rifampin.
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increase in resistance to ﬁve drugs.
Among all cases (50 patients, 100 isolates), DR increased 10% and
MDR 18%. The highest increases were to EMB and PZA, both 32%.
Decreases inresistancewere foundtoonedrug(14%)andto twodrugs
(2%), while therewas a 2% increase in resistance to three drugs and to
four drugs, and a 22% increase in resistance to ﬁve drugs (Table 3).
In relation to the second isolate (of 50 patients with two
isolates), 18% (9/50) remained free of drug resistance, 12% (6/50)
becameDR, 26% (13/50) showed the same resistance level, and 42%
(21/50) showed higher resistance. Of the latter group, resistance
increased to one drug (42.9%; 9/21), two drugs (47.6%; 10/21), and
three drugs (9.5%; 2/21). Of those who had the same resistance
level in both isolates (26%; 13/50), 38.5% (5/13) showed resistance
to ﬁve drugs.
4. Discussion
In spite of the fact that there is a National Control Program in
Mexico, TB continues to be a public health problem. Previous
reports have indicated a high prevalence of drug resistance in some
Mexican populations.4,11,18,20–25 In the 6 years from 1997 to 2002,
we found that 34.9% of M. tuberculosis isolates in Sinaloa were
resistant to one or more ﬁrst-line anti-tuberculosis drugs (DR),
with 17.9% resistant to both INH and RIF (MDR), with an increasing
trend in both of these categories.
The overall resistance rate found in this study (34.9%) was
higher than that found in the unique national survey (21.5%)
carried out by the Mexican Secretariat of Health and the CDC in
1997 in three states of Mexico (Baja California, Oaxaca, and
Sinaloa),18 and higher than the median rate (20%) reported for the
Global Project (WHO/IUATLD).3 Furthermore, the DR level in
Sinaloa was also higher than that found in several other states: in
Mexico State and Mexico City (30.0%; 1991–1993),25 in Veracruz
(25%; 1995–1999),12 and in Baja California (25.8%; 1998–1999).23
Moreover, the result of the present study was almost the same as
that reported in San Luis Potosi (36.0%; 2003–2004),22 but was
lower than that reported in Chiapas (72.2%; 1992)26 and Baja
California (41%; 1995–1996).27
In this study, the MDR rate (17.9%) was higher than that
determined in the unique national survey (7.4%),18 and higher than
themedian rate from theWHO/IUATLD Global Project (5.3%).3 ThisMDR level in Sinaloa was also higher than that found in two other
states: in Veracruz (6.2%; 1995–1999)3,12 and in Baja California
(13.3%).23 Moreover, it was very similar to that found in San Luis
Potosi (16%; 2003–2004),22 but was lower than that reported in
Mexico State and Mexico City (64.0%)25 and Chiapas (53.0%).26 It is
very worrisome to note the high level of MDR among DR cases, and
that trends of DR and MDR (from 1997 to 2002) showed a
statistically signiﬁcant increase (1.2% per year; Figure 1). Equally
alarming is that the highest levels of drug resistance were for INH
(29.8%) and RIF (19.2%, Table 2), as these are the most potent anti-
TB drugs for primary treatment as suggested by the WHO.
Among new cases from 1997 to 2002, DR was higher (21.2%)
than that reported by the national survey (12.9%)18 and by all the
other Mexican studies considered, although it was similar to that
found in Veracruz (20.7%; 1995–1998).11 MDR (4.9%) was also
higher than that found in all the other Mexican studies considered,
except for the rate found in Baja California (10%; 1995–1996)27 and
in Mexico State and Mexico City (6.0%; 1991–1993).25 Among
previously treated cases from 1997 to 2002, DR (64.8%) and MDR
(47.8%) rates were higher than those reported nationally (50.5%
and 22.4%, respectively)18 and in all other studies in Mexican
populations mentioned: in Mexico State and Mexico City (46.0%
and 35.0%, respectively),25 in Veracruz (49.2% and 23.8%, respec-
tively),11 and in Baja California (48.9% and 30.6%, respectively).23
These data suggest that in Sinaloa, DRM. tuberculosis is becoming a
grave problem, even graver if we consider that for practical
purposes the presence of resistant strains of M. tuberculosis in a
community is always a consequence of inadequate TB treatment.8
In agreement with this observation is the fact that among
previously treated cases, 64.8% of patients had DR and 47.8% MDR.
Drug resistance levels in the follow-up phase (2003–2004)
generally remained moderate or high. However, it is important to
mention that there were decreases in the levels of DR (21.2% to
17.5%) and MDR (4.9% to 0.0%) among new cases. This could be
explained by the decrease in cases studied in this stage and/or by a
better population control of TB treatment. The latterwould suggest
an intermittent control of the Sinaloa drug-resistant TB during this
period.
In the third stage of the analysis where we compared the
resistance proﬁles of a group of patients with two strains of M.
tuberculosis (recurrent or chronic patients) from 1997 to 2005,
there were important increases in drug resistance in the second
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drug resistance among all patients: 12% (6/50) of all patients
became DR and 60% (21/35) patients with some form of drug
resistance developed greater resistance proﬁles. These increases
resulting from the periodic evaluation of susceptibility show that
there could be important treatment failure and relapse in these
patients, perhaps because of inadequate or discontinuous treat-
ment, suggesting a poor control of TB at the population level.
In conclusion, the results of this study for theperiod1997–2005 in
Sinaloa reveal moderate or high levels of drug resistance compared
with the unique national survey,18 the WHO/IUATLD Global Project
(Report No. 4; 2008),3 and other previous studies in Mexican
populations,4 with trends towards an increase in drug resistance.
Althoughtheﬁndings fromtheuniquenational surveyof1997,which
included the state of Sinaloa,18 led to a limitation of increases in drug
resistance by the addition of EMB to the TB treatment regimen (INH/
RIF/EMB/PZA (RIPE) in new case-patients, from the year 2000),28 the
relatively high prevalence of MDR and the increasing rates of EMB
resistance found in the later years of the present study (Tables 2 and
3), suggest a chronic public health problem that, if not contained
rapidly, may be out of control in coming years.
This suggests that continuous efforts should be directed at the
prevention of TB and the effective application of TB control
programs (DOTS strategy) in Sinaloa. The latter strategy is vital, as
treatment failure and relapse, perhaps because of inadequate or
discontinuous treatment, is probably an important factor in the
patients studied. The probable poor control of TB at the population
level is consistent with the high levels of resistance occurring
among previously treated cases. However, there are other possible
factors, such as acquired resistance and transmitted primary
resistance. Therefore, the magnitude of potential failure and
relapse suggested in this study does not allow for deﬁnitive
conclusions to be drawn on the TB control program.
The limitations of the current study include possible biases that
could limit the validity of results, such as the methods of patient
selection and data collection, including data related to treatment
history, which was used to differentiate between new and
previously treated cases. On the other hand, our study sample
consisted of all strains of M. tuberculosis from TB patients at the
only mycobacterial laboratory of Sinaloa State, which ensures
some representation of this population. Thus despite possible
limitations, the current study strongly suggests problems in the
control of TB drug resistance in the Sinaloa population.
This is the ﬁrst study reporting data on drug resistance trends in
Sinaloa in relation to the current regimens of TB treatment (RIPE in
newcase-patients), and represents a follow-upof the national survey
of 1997 (BajaCalifornia,Oaxaca, andSinaloa).18 Finally, in accordance
with the WHO/IUATLD (Report No. 4, 2008),3 Mexico has started a
nationwide survey and has plans to testMDR-TB isolates for second-
line drug resistance at a supranational reference laboratory. This
survey must be considered a priority for the planning of the future
management of MDR-TB and probably XDR-TB in Mexico.
Acknowledgements
This work was supported by the Secretariat of Health of the
State of Sinaloa (TB Program). We thank the staff of the Institute of
Epidemiological Diagnosis and Reference (InDRE, Mexico City) for
their support in the susceptibility testing. We thank Bruce Allan
Larsen for reviewing the use of English in this manuscript.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global
trends in resistance to antituberculosis drugs. World Health Organization–International Union against Tuberculosis and Lung Disease Wo rking Group on
Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001;344:
1294–303.
2. Gupta R, Espinal MA, Raviglione MC. Tuberculosis as a major global health
problem in the 21st century: a WHO perspective. Semin Respir Crit Care Med
2004;25:245–53.
3. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveil-
lance 2002-2007. Anti-tuberculosis drug resistance in the world. Report No. 4.
WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO; 2008.
4. Zazueta-Beltran J, Leon-Sicairos C, Canizalez-Roman A. Drug resistant Myco-
bacterium tuberculosis in Mexico. J Infect Dev Ctries 2009;3:162–8.
5. World Health Organization. WHO report on the tuberculosis epidemic. WHO/
TB/97/224. Geneva, Switzerland: WHO; 1997.
6. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tubercu-
losis incidence and their determinants in 134 countries. Bull World Health Organ
2009;87:683–91.
7. Caminero JA. Management of multidrug-resistant tuberculosis and patients in
retreatment. Eur Respir J 2005;25:928–36.
8. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and
controversies. Int J Tuberc Lung Dis 2006;10:829–37.
9. Caminero Luna JA. [Origin, present, and future of tuberculosis resistance] (in
Spanish). Arch Bronconeumol 2001;37:35–42.
10. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW.
The emergence of drug-resistant tuberculosis in New York City. N Engl J Med
1993;328:521–6.
11. Garcia-Garcia ML, Jimenez-Corona ME, Ponce-de-Leon A, Jimenez-Corona A,
Palacios-Martinez M, Balandrano-Campos S, et al. Mycobacterium tuberculosis
drug resistance in a suburban community in southern Mexico. Int J Tuberc Lung
Dis 2000;4:S168–70.
12. Garcı´a-Garcı´a ML, Sifuentes-Osornio J, Jime´nez-Corona ME, Ponce-de-Leo´n
A, Jime´nez-Corona A, Bobadilla-del Valle M, et al. Drug resistance of Myco-
bacterium tuberculosis in Orizaba, Veracruz. Implications for the tuberculosis
prevention and control program] (in Spanish). Rev Invest Clin 2001;53:
315–23.
13. Centers for Disease Control and Prevention (CDC). Emergence ofMycobacterium
tuberculosiswith extensive resistance to second-line drugs—worldwide, 2000–
2004. MMWR Morb Mortal Wkly Rep 2006;55:301–5.
14. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al.
Global surveillance for antituberculosis drug resistance, 1994–1997. World
Health Organization–International Union against Tuberculosis and Lung Dis-
easeWorking Gro up on Anti-Tuberculosis Drug Resistance Surveillance. N Engl
J Med 1998;338:1641–9.
15. WHO/IUATLDGlobal Project on Anti-tuberculosis Drug Resistance Surveillance.
Anti-tuberculosis drug resistance in theworld. Report 2: Prevalence and trends.
WHO/CDC/TB/2000.278. Geneva, Switzerland: WHO; 2000.
16. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance
1999–2002. Anti-tuberculosis drug resistance in the world. Report No. 3. WHO/
CDC/TB/2004.343. Geneva, Switzerland: WHO; 2004.
17. Baez-Saldana AR, Perez-Padilla JR, Salazar-Lezama MA. [Epidemiology of
tuberculosis in Mexico, 1981–1998. Inconsistencies between reports of the
WHO and the Ministry of Health] (in Spanish). Salud Publica Mex 2003;45:
78–83.
18. Granich RM, Balandrano S, Santaella AJ, Binkin NJ, Castro KG, Marquez-Fiol A,
et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican
states, 1997. Arch Intern Med 2000;160:639–44.
19. Department of Health. Sistema Unico de Informacio´n para la Vigilancia Epi-
demiolo´gica/Direccio´n General de Epidemiologı´a/SSA. Mexico: Department of
Health; 2010. Available at: http://www.dgepi.salud.gob.mx (accessed January
11, 2010).
20. Zazueta-Beltran J, Muro-Amador S, Flores-Gaxiola A, Llausas-Magana E, Leon-
Sicairos N, Canizalez-Roman A. High rates of multidrug-resistant Mycobacteri-
um tuberculosis in Sinaloa State, Mexico. J Infect 2007;54:411–2.
21. Blancarte ML, Anzaldo JG, Balandrano SS. [Primary resistance ofMycobacterium
tuberculosis] (in Spanish). Salud Publica Mex 1982;24:321–7.
22. Fragoso Morales LE, Pastor Durango P, Magana Aquino M, Fajardo Santana H,
Bobadilla de Valle M, Carrera de la Torre B, et al. [Risk factors for drug-resistant
tuberculosis in San Luis Potosi, Mexico 2003–2004] (in Spanish). Salud Publica
Mex 2006;48:361–2.
23. Laniado-Laborin R, Cabrales-Vargas N. Tratamiento acortado estrictamente
supervisado: Estrategia necesaria, pero no suﬁciente para controlar la tuber-
culosis en Baja, California, Me´xico. Rev Inst Nal Enf Resp Mex 2000;13:23–7.
24. Olvera Castillo R. Farmacorresistencia secundaria en tuberculosis. Tendencia en
el Instituto Nacional de Enfermedades Respiratorias. Rev Inst Nal Enf Resp Mex
2001;14:151–9.
25. Sifuentes Osornio J. Epidemiologı´a de la resistencia antimicrobiana en Myco-
bacterium tuberculosis en Me´xico. Gac Me´d Me´x 2003;139:477–80.
26. Alvarez-Gordillo GC, Halperin-Frisch D, Blancarte-Melendres L, Vazquez-Cas-
tellanos J. [Risk factors for antitubercular drug resistance in Chiapas, Mexico]
(in Spanish). Salud Publica Mex 1995;37:408–16.
27. Peter CR, Schultz E, Moser K, Cox M, Freeman R, Ramirez-Zetina M, Lomeli MR.
Drug-resistant pulmonary tuberculosis in the Baja California–San Diego County
border population. West J Med 1998;169:208–13.
28. Secretarı´a de Salud. Modiﬁcacio´n a la Norma Oﬁcial Mexicana NOM-006-SSA2-
1993. Para la prevencio´n y control de la tuberculosis en la atencio´n primaria a la
salud. Diario Oﬁcial de la Federacio´n, 2000; Octubre: 9–33. Ministry of Health:
Mexico; 2000.
